Literature DB >> 6178290

Flow cytometry analysis of T lymphocytes in sarcoidosis.

Y Pacheco, G Cordier, M Perrin-Fayolle, J P Revillard.   

Abstract

To examine the immunologic alterations in patients with sarcoidosis we characterized the cell cycle phase of T lymphocytes that were collected from peripheral blood and from bronchoalveolar lavage fluid. T-cell DNA and RNA contents were measured at the single cell level using flow cytometry after staining with the metachromatic fluorochrome acridine orange. T-enriched lymphocyte suspensions were obtained from peripheral blood and from bronchoalveolar lavage in 17 patients with histologically-proved sarcoidosis (10 patients, stage I and 7 patients, stage II) and in 4 patients with acute extrinsic hypersensitivity pneumonitis (AEHP). The percentages of cells in the S + (GS + M) phase in the peripheral blood of the patients with sarcoidosis did not differ from those of healthy control subjects. With bronchoalveolar lavage, however, elevated numbers of T cells in the S + (G2 + M) phase were found in the patients with AEHP and in those with stage II sarcoidosis when compared to patients with stage I sarcoidosis. The cellular RNA content of T lymphocytes from the peripheral blood showed a typical bimodal distribution without difference between patients and control subjects. Conversely, T lymphocytes obtained by bronchoalveolar lavage from patients with AEHP and sarcoidosis had a homogeneous low RNA content which differed from that of T lymphocytes from the blood from that of in vitro phytohemagglutinin-stimulated lymphocytes. These findings provide a new approach to the study of the mechanisms of local T-cell activation in sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178290     DOI: 10.1016/0002-9343(82)90930-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Differentiation and activation phenotypes of lung T lymphocytes differ from those of circulating T lymphocytes.

Authors:  B L Davidson; J Faust; S Pessano; R P Daniele; G Rovera
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

2.  Increased DNA and/or RNA content of synovial fluid cells in rheumatoid arthritis: a flow-cytometry study.

Authors:  B Bonvoisin; G Cordier; J P Revillard; E Lejeune; M Bouvier
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

3.  Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients.

Authors:  G Semenzato; C Agostini; L Trentin; R Zambello; M Chilosi; A Cipriani; E Ossi; M R Angi; L Morittu; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

4.  Immunohistochemical analysis of sarcoid granulomas. Evaluation of Ki67+ and interleukin-1+ cells.

Authors:  M Chilosi; F Menestrina; P Capelli; L Montagna; M Lestani; G Pizzolo; A Cipriani; C Agostini; L Trentin; R Zambello
Journal:  Am J Pathol       Date:  1988-05       Impact factor: 4.307

5.  Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis.

Authors:  A Venet; A J Hance; C Saltini; B W Robinson; R G Crystal
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

6.  Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset.

Authors:  C Saltini; J R Spurzem; J J Lee; P Pinkston; R G Crystal
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Whole exome sequencing in three families segregating a pediatric case of sarcoidosis.

Authors:  Alain Calender; Pierre Antoine Rollat Farnier; Adrien Buisson; Stéphane Pinson; Abderrazzaq Bentaher; Serge Lebecque; Harriet Corvol; Rola Abou Taam; Véronique Houdouin; Claire Bardel; Pascal Roy; Gilles Devouassoux; Vincent Cottin; Pascal Seve; Jean-François Bernaudin; Clarice X Lim; Thomas Weichhart; Dominique Valeyre; Yves Pacheco; Annick Clement; Nadia Nathan
Journal:  BMC Med Genomics       Date:  2018-03-06       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.